SYRA vs TALK vs ACMR vs OPRX vs CLOV

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus -9. 5% for Syra Health Corp. Class A Common Stock (SYRA). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 24.

6x versus Talkspace, Inc. at 129. 5x. On forward P/E, OptimizeRx Corporation is actually cheaper at 7. 0x.

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +133. 4%, compared to -87. 3% for OptimizeRx Corporation (OPRX). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus SYRA's -83. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Syra Health Corp.

Class A Common Stock (SYRA) is the lower-risk stock at 0. 19β versus ACM Research, Inc. 's 3. 24β — meaning ACMR is approximately 1633% more volatile than SYRA relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 4% versus 16% for ACM Research, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus -9. 5% for Syra Health Corp. Class A Common Stock (SYRA). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACM Research, Inc.

(ACMR) is the more profitable company, earning 10. 4% net margin versus -12. 4% for Syra Health Corp. Class A Common Stock — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACMR leads at 12. 1% versus -12. 5% for SYRA. At the gross margin level — before operating expenses — OPRX leads at 67. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.

0x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 58. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.

In this comparison, ACMR (0.

2% yield) pays a dividend. SYRA, TALK, OPRX, CLOV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Syra Health Corp.

Class A Common Stock (SYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 19)). ACM Research, Inc. (ACMR) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYRA: -83. 3%, ACMR: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SYRA (Healthcare) and TALK (Healthcare) and ACMR (Technology) and OPRX (Healthcare) and CLOV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SYRA is a small-cap quality compounder stock; TALK is a small-cap high-growth stock; ACMR is a small-cap high-growth stock; OPRX is a small-cap high-growth stock; CLOV is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.